Drug intelligence / Profile preview

CSPCHA131

Development stage: Phase 1
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules

Overview

CSPCHA131 is an investigational drug developed for the treatment of advanced solid tumors. Its mechanism of action has not been disclosed or remains unknown. The drug is being evaluated in early-phase clinical trials, specifically Phase 1, for oncology indications involving unspecified solid tumors. There are no known adverse events reported to date, and it has not received any regulatory approvals or special designations.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on CSPCHA131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSPCHA131.

Explore the full profile